N

Nxera Pharma Tech Stack

GPCR-focused drug discovery using AI and structure-based design

Biotechnology Research Tokyo, Tokyo 201–500 employees Founded 1990 Public Company

Nxera Pharma is a public biopharma company advancing 30+ programs across neurology, immunology, and metabolic disorders, anchored by its proprietary NxWave platform for GPCR-targeted drug discovery. The tech stack—Python, PyTorch, TensorFlow, RDKit, and RAG—reflects active investment in AI-driven ligand discovery and cheminformatics automation. Current hiring is concentrated in research and data roles at senior and VP levels in the UK, suggesting focused expansion of computational and AI capabilities rather than broad-based growth.

Tech Stack 13 technologies

Core StackRAG Python Java C++ AWS PyTorch TensorFlow RDKit AWS CDK SQL GCP Azure JAX

What Nxera Pharma Is Building

◆Challenges

Scale ai automation
Ai integration with experimental pipelines
Building high throughput ai discovery engine
Unifying chemical biological structural data
Implementing fair data principles
Expanding ai capabilities
Accelerating drug discovery

▲Active Projects

Gpcr discovery engine
Nxwavetm platform integration
Ai-driven ligand discovery
Internal cheminformatics platform development
Fair data principles implementation
Scalable ai infrastructure deployment
Mlops workflows
Standardised data systems
Nxwave platform

Hiring Activity

Minimal5 roles · 0 in 30d

Department

Research

4

Data

1

Seniority

Senior

2

VP

2

Director

1

Company intelligence

Find more companies like Nxera Pharma by tech stack, pain points and active projects

Get started free

About Nxera Pharma

Nxera Pharma (formerly Sosei Heptares) is a publicly traded biopharma company headquartered in Tokyo with R&D and commercial operations across Japan, the UK, Switzerland, and South Korea. The company develops specialty medicines targeting unmet needs in neurology, gastrointestinal disorders, immunology, metabolic diseases, and rare conditions. Its core asset is the NxWave platform, a structure-based drug discovery engine optimized for GPCR targets, which feeds an internal pipeline of preclinical and clinical-stage candidates. The company also commercializes select products in Japan and partners with leading pharma and biotech firms to expand its reach.

HeadquartersTokyo, Tokyo

Company Size201–500 employees

Founded1990

Hiring MarketsUnited Kingdom

Frequently Asked Questions

What is Nxera Pharma's drug discovery platform?

NxWave is Nxera's proprietary GPCR-targeted structure-based drug discovery platform. It generates best- or first-in-class candidates across neurology, GI, immunology, metabolic disorders, and rare diseases. The platform underpins an internal pipeline of 30+ active programs.

What AI and computational tools does Nxera Pharma use?

Nxera's stack includes Python, PyTorch, TensorFlow, RDKit, RAG, SQL, and cloud infrastructure (AWS, GCP, Azure). Active projects include an AI-driven ligand discovery engine, internal cheminformatics platform, and MLOps workflows for scaling automation.

Where is Nxera Pharma headquartered?

Nxera is headquartered in Tokyo, Japan, with R&D and operational hubs in Osaka (Japan), London and Cambridge (UK), Basel (Switzerland), and Seoul (South Korea). The company is listed on the Tokyo Stock Exchange under ticker 4565.